Understanding the Mechanisms of Drug Resistance in Non-Small Cell Lung Cancer Potential Therapeutic Approaches

Afnan  Ali Shah; Waqar Ahmad  Tahir; Owais Nawaz Khan; Ayesha  Abid; Yasar Umar  Khan; Talha  Mazhar

doi:10.62497/IRABCS.2024.65

Authors

Afnan Ali Shah Bannu Medical College, Bannu, Pakistan Author https://orcid.org/0009-0000-8648-6504
Waqar Ahmad Tahir Medical Officer, Khalifa Gull Nawaz Teaching Hospital MTI Bannu, Pakistan Author https://orcid.org/0009-0009-5555-2332
Owais Nawaz Khan Khyber Medical College, Peshawar. Author https://orcid.org/0009-0000-4757-1714
Ayesha Abid Nowshera Medical College, Nowshera, Pakistan Author https://orcid.org/0009-0000-0974-9147
Yasar Umar Khan Saidu Medical College, Swat, Pakistan Author https://orcid.org/0009-0007-8308-8819
Talha Mazhar Saidu Medical College, Swat, Pakistan Author https://orcid.org/0009-0009-2421-6328

DOI:

https://doi.org/10.62497/IRABCS.2024.65

Keywords:

Non-small cell lung cancer, drug resistance, EGFR mutations, epigenetic modifications, tumor microenvironment, personalized therapy.

Abstract

Background: Drug resistance is a major obstacle to the successful treatment of non-small cell lung cancer (NSCLC), the most common subtype of lung cancer. The purpose of this research was to look at possible treatment approaches and the processes behind drug resistance in non-small cell lung cancer.

Methods: From March 2022 to February 2024, a prospective observational research was carried out at Lady Reading Hospital in Peshawar. 128 NSCLC patients in all were enrolled. Next-generation sequencing, DNA methylation tests, and immunological profiling were used to examine the genetic, epigenetic, and environmental components linked to medication resistance. Multivariate logistic regression, t-tests, chi-square tests, and Kaplan-Meier survival analysis were among the statistical techniques used.

Results: T790M mutations contributed to resistance, with EGFR mutations found in 35% of patients. Ten percent of patients had MET amplifications, while seven percent of patients had ALK rearrangements. In resistant cancers, epigenetic changes such as hypoacetylation of histones and hypermethylation of CDKN2A were common. Immunosuppressive cells and cancer-associated fibroblasts were abundant in the tumor microenvironment. The median overall survival (OS) of patients with drug-resistant NSCLC was 14 months, a substantial decrease from the 22 months seen in patients without resistance (p < 0.001).

Conclusions: The research emphasizes how genetic, epigenetic, and microenvironmental variables all play a role in the complex process of medication resistance in non-small cell lung cancer. Molecular profiling and targeted medicines along with personalized treatment techniques are critical to overcome resistance and enhancing patient outcomes. Larger, more varied populations and the creation of cutting-edge treatment approaches should be the main topics of future study.

Downloads

Download data is not yet available.

Author Biography

Waqar Ahmad Tahir , Medical Officer, Khalifa Gull Nawaz Teaching Hospital MTI Bannu, Pakistan

ECFMG certified

References

Sosa Iglesias V, Giuranno L, Dubois LJ, Theys J, Vooijs M. Drug resistance in non-small cell lung cancer: a potential for NOTCH targeting?. Frontiers in oncology. 2018 Jul 24;8:267. https://doi.org/10.3389/fonc.2018.00267

Liu WJ, Du Y, Wen R, Yang M, Xu J. Drug resistance to targeted therapeutic strategies in non-small cell lung cancer. Pharmacology & therapeutics. 2020 Feb 1;206:107438.

Terlizzi M, Colarusso C, Pinto A, Sorrentino R. Drug resistance in non-small cell lung Cancer (NSCLC): Impact of genetic and non-genetic alterations on therapeutic regimen and responsiveness. Pharmacology & therapeutics. 2019 Oct 1;202:140-8. https://doi.org/10.1016/j.pharmthera.2019.06.005

Wang M, Herbst RS, Boshoff C. Toward personalized treatment approaches for non-small-cell lung cancer. Nature medicine. 2021 Aug;27(8):1345-56.

Lim ZF, Ma PC. Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapy. Journal of hematology & oncology. 2019 Dec 9;12(1):134. https:// doi.org/10.1186/s13045-019-0818-2

Horvath L, Thienpont B, Zhao L, Wolf D, Pircher A. Overcoming immunotherapy resistance in non-small cell lung cancer (NSCLC)-novel approaches and future outlook. Molecular Cancer. 2020 Dec;19:1-5.

Min HY, Lee HY. Mechanisms of resistance to chemotherapy in non-small cell lung cancer. Archives of pharmacal research. 2021 Feb;44(2):146-64. https:// doi.org/10.1007/s12272-021-01312-y

Hsu JH, Chang PM, Cheng TS, Kuo YL, Wu AT, Tran TH, Yang YH, Chen JM, Tsai YC, Chu YS, Huang TH. Identification of withaferin A as a potential candidate for anti-cancer therapy in non-small cell lung cancer. Cancers. 2019 Jul 17;11(7):1003.

Murtuza A, Bulbul A, Shen JP, Keshavarzian P, Woodward BD, Lopez-Diaz FJ, Lippman SM, Husain H. Novel third-generation EGFR tyrosine kinase inhibitors and strategies to overcome therapeutic resistance in lung cancer. Cancer Research. 2019 Feb 15;79(4):689-98. https://doi.org/10.1158/0008-5472.CAN-18-1281

Koulouris A, Tsagkaris C, Corriero AC, Metro G, Mountzios G. Resistance to TKIs in EGFR-mutated non-small cell lung cancer: from mechanisms to new therapeutic strategies. Cancers. 2022 Jul 8;14(14):3337. https://doi.org/10.3390/cancers14143337

Lim SM, Syn NL, Cho BC, Soo RA. Acquired resistance to EGFR targeted therapy in non-small cell lung cancer: Mechanisms and therapeutic strategies. Cancer treatment reviews. 2018 Apr 1;65:1-0.

Laface C, Maselli FM, Santoro AN, Iaia ML, Ambrogio F, Laterza M, Guarini C, De Santis P, Perrone M, Fedele P. The resistance to EGFR-TKIs in non-small cell lung cancer: from molecular mechanisms to clinical application of new therapeutic strategies. Pharmaceutics. 2023 May 27;15(6):1604. https://doi.org/10.3390/pharmaceutics15061604

Eser PÖ, Jänne PA. TGFβ pathway inhibition in the treatment of non-small cell lung cancer. Pharmacology & therapeutics. 2018 Apr 1;184:112-30.

Halliday PR, Blakely CM, Bivona TG. Emerging targeted therapies for the treatment of non-small cell lung cancer. Current oncology reports. 2019 Mar;21:1-2. https://doi.org/10.1007/s11912-019-0770-x

Florczuk M, Szpechcinski A, Chorostowska-Wynimko J. miRNAs as biomarkers and therapeutic targets in non-small cell lung cancer: current perspectives. Targeted oncology. 2017 Apr;12:179-200.

Ramisetty S, Kulkarni P, Bhattacharya S, Nam A, Singhal SS, Guo L, Mirzapoiazova T, Mambetsariev B, Mittan S, Malhotra J, Pisick E. A systems biology approach for addressing cisplatin resistance in non-small cell lung cancer. Journal of Clinical Medicine. 2023 Jan 11;12(2):599. https://doi.org/10.3390/jcm12020599

Walsh RJ, Soo RA. Resistance to immune checkpoint inhibitors in non-small cell lung cancer: biomarkers and therapeutic strategies. Therapeutic advances in medical oncology. 2020 Jul;12:1758835920937902.

Tong CW, Wu WK, Loong HH, Cho WC, To KK. Drug combination approach to overcome resistance to EGFR tyrosine kinase inhibitors in lung cancer. Cancer letters. 2017 Oct 1;405:100-10. https://doi.org/10.1016/j.canlet.2017.07.023